News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
BioRelix Pharmaceuticals Enters Antibacterial Collaboration with Merck & Co., Inc.
October 4, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW HAVEN, Conn.--(BUSINESS WIRE)--BioRelix, Inc. today announced that it has entered into a research collaboration agreement with a subsidiary of Merck & Co., Inc. to identify new antibacterial drug candidates.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Merck & Co.
MORE ON THIS TOPIC
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
·
3 min read
·
Tristan Manalac
Manufacturing
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
May 21, 2026
·
2 min read
·
Nick Paul Taylor
Leadership
Vaxart seeks shareholder support as battle over stock split brews
May 21, 2026
·
2 min read
·
Tristan Manalac
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
